Personalized testing for safety and effective

Testing patients for genetic mutations that affect the body’s response to common drugs is completely fair to the United Kingdom National Health Service (NHS), according to a report published by the British Pharmacology Society and the Royal Medical College. And it must be integrated quickly.

Report- Individual prescription: Use pharmacological genomics to improve patient outcomes – A type of test called pharmacological genomics testing has been rolled out throughout the NHS to evenly distribute the drug to all patients at doses that appear to be safe, effective, and have minimal side effects. I will explain how to do it. ..

Whether the drug works, whether it causes serious side effects, and the required dose vary greatly from person to person. Scientists have established the genetic cause of such variations in over 40 drugs.

Several pharmacological genomics tests are already available on the NHS, including a drug called abacavir used to treat HIV and a drug called 5-fluorouracil used to treat certain cancers. However, tests are not available on the NHS for most of these 40 medicines. These include commonly prescribed medications such as painkillers, beta blockers, and antidepressants.

One example is an antibiotic called gentamicin, which is used intravenously to treat serious infections. About 1 in 500 people have a specific genetic mutation that makes them more susceptible to hearing loss with this type of drug. Another example is codeine, a very widely used painkiller. About 8% of the UK population lacks the genes that allow the drug to function properly. In other words, the pain cannot be relieved.

The explanation of the report is British Journal of Clinical PharmacologyAlmost 99% of people explain that they have at least one of these genetic variants.

Professor Sir Munir Pirmohamed, Dean of Medicine at the University of Liverpool and Chair of the Working Group on the Report, said: The UK is a world leader in genomic medicine, and conducting more extensive pharmacological genomics trials will further demonstrate UK leadership.

“Today, we are calling on government and medical services to ensure that patients across the UK are provided with these tests when there is evidence of their usefulness. For patients, this is what they do. It means that the medicines you take are likely to be more effective and safer.^st In this century, we are more personalized to administer the right drug at the right dose to patients to improve the efficacy and safety of the drug, from the paradigm “one drug and one dose fits all”. You need to move to the approach that was done. “

This report provides a set of recommendations to help deploy pharmacological genomics testing in general practitioners, hospitals and clinics across the UK. These include: Central funding from relevant test run processes in all four countries to avoid zip code lottery that can exacerbate inequality. Education and training; Pharmacology genomics advisory services for physicians.

Pharmacological genomics testing services should also be evaluated through audits, research, and patient input to identify more interactions between genes and drugs, improve existing studies, and assess uptake. We encourage you to fund further research.

Importantly, patients and the general public need to be involved in the design and creation of services. Dr Emma Magaver, a clinician at Queen Mary University of London, co-author of the report, said: We need to gain a better understanding of pharmacological genomics testing, how it works, and the health benefits it offers. The public needs to be confident that their genetic data is safe and confidential, and patients to ensure that our pharmacological genomics testing services are fit for purpose and meet their needs. And the opinion of the people is needed. “

Professor Mark Colefield, Vice-Principal of Health at Queen Mary University of London and President-elect of the British Society of Pharmacology, who contributed to the report, said: This means that it has the world’s first potential to integrate pharmacological genomics testing into the NHS. This report provides a blueprint to identify the resources and actions required for pharmacogenomics to become normal care at the NHS over the next three years. “

Sir David Prior, Chair of the NHS England, said in the preface of the report: We always knew we were different, but now we know why. And that knowledge can be used to predict illness, diagnose illness, and treat illness on an individual basis. This will revolutionize medicine and, in combination with a digitally driven population health approach, will radically change traditional care models. …[pharmacogenomics] Is the future and could help provide a new, up-to-date, personalized healthcare system for 2022 … “

Dr. Andrew Goddard, President of the Royal College of Physicians, said: This is an area that has not traditionally existed in the online systems and tools that doctors use on a daily basis. We hope that this report will be a starting point for the effective functioning of genomics in routine clinical practice. “

Ravi Sharma, UK Director of the Royal Pharmaceutical Society, who belonged to the working group of the report, said: A place for patients. As recommended in the report, the infrastructure for creating pharmacogenomics services in all integrated care systems has been established and incorporated into clinical pathways across disciplines to improve individual patient care. We want pharmacists to take important leadership in interdisciplinary teams. “